{"id":746075,"date":"2019-02-21T06:45:00","date_gmt":"2019-02-21T06:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/"},"modified":"2025-05-12T08:58:19","modified_gmt":"2025-05-12T12:58:19","slug":"merck-to-acquire-immune-design","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/","title":{"rendered":"Merck to Acquire Immune Design"},"content":{"rendered":"<p class=\"bwalignc\">       Acquisition Bolsters Capabilities in Vaccine Development for        Infectious Diseases and Cancer     <\/p>\n<p>KENILWORTH, N.J. &amp; SEATTLE &amp; SOUTH SAN FRANCISCO, Calif.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Immune Design (NASDAQ:IMDZ), today announced that the companies have<br \/>\n      entered into a definitive agreement under which Merck, through a<br \/>\n      subsidiary, will acquire Immune Design for $5.85 per share in cash for<br \/>\n      an approximate value of $300 million.\n    <\/p>\n<p>\n      \u201cScientists at Immune Design have established a unique portfolio of<br \/>\n      approaches to cancer immunization and adjuvant systems designed to<br \/>\n      enhance the ability of a vaccine to protect against infection, which<br \/>\n      could meaningfully improve vaccine development,&#8221; said Dr. Roger M.<br \/>\n      Perlmutter, president, Merck Research Laboratories. \u201cThis acquisition<br \/>\n      builds upon Merck\u2019s industry-leading programs that harness the power of<br \/>\n      the immune system to prevent and treat disease.\u201d\n    <\/p>\n<p>\n      Immune Design is a late-stage immunotherapy company employing<br \/>\n      next-generation <i>in vivo<\/i> approaches to enable the body&#8217;s immune<br \/>\n      system to fight disease. The company&#8217;s proprietary technologies, GLAAS<sup>\u00ae<\/sup><br \/>\n      and ZVex<sup>\u00ae<\/sup>, are engineered to activate the immune system&#8217;s<br \/>\n      natural ability to generate and\/or expand antigen-specific cytotoxic<br \/>\n      immune cells to fight cancer and other chronic diseases.\n    <\/p>\n<p>\n      \u201cMerck has a rich history of discovery and innovation and a strong track<br \/>\n      record of developing meaningful therapeutics and vaccines,\u201d said Dr.<br \/>\n      Carlos Paya, president and chief executive officer, Immune Design. \u201cWe<br \/>\n      believe this agreement creates shareholder value by positioning our<br \/>\n      technologies and capabilities for long-term success with a leading,<br \/>\n      research-driven biopharmaceutical company.\u201d\n    <\/p>\n<p>\n      Under the terms of the acquisition agreement announced today, Merck,<br \/>\n      through a subsidiary, will initiate a tender offer to acquire all<br \/>\n      outstanding shares of Immune Design. The closing of the tender offer<br \/>\n      will be subject to certain conditions, including the tender of shares<br \/>\n      representing at least a majority of the total number of Immune Design\u2019s<br \/>\n      outstanding shares, the expiration of the waiting period under the<br \/>\n      Hart-Scott-Rodino Antitrust Improvements Act and other customary<br \/>\n      conditions. Upon the successful completion of the tender offer, Merck<br \/>\n      will acquire all shares not acquired in the tender through a second-step<br \/>\n      merger. The transaction is expected to close early in the second quarter<br \/>\n      of 2019.\n    <\/p>\n<p>\n      Credit Suisse acted as financial advisor to Merck in this transaction<br \/>\n      and Gibson, Dunn &amp; Crutcher LLP as its legal advisor. Lazard acted as<br \/>\n      financial advisor to Immune Design and Cooley LLP as its legal advisor.\n    <\/p>\n<p>\n      <b>Important Information about the Tender Offer<\/b>\n    <\/p>\n<p>\n      The tender offer described in this press release (the \u201cOffer\u201d) has not<br \/>\n      yet commenced. This press release is for informational purposes only and<br \/>\n      is neither an offer to purchase nor a solicitation of an offer to sell<br \/>\n      any shares of the common stock of Immune Design (\u201cIMDZ\u201d) or any other<br \/>\n      securities. At the time the planned tender offer is commenced, a tender<br \/>\n      offer statement on Schedule TO, including an offer to purchase, a letter<br \/>\n      of transmittal and related documents, will be filed by Merck Sharp &amp;<br \/>\n      Dohme Corp. (\u201c<span class=\"bwuline\">Merck<\/span>\u201d) and Cascade Merger<br \/>\n      Sub Inc., a wholly-owned subsidiary of Merck (\u201c<span class=\"bwuline\">Buyer<\/span>\u201d),<br \/>\n      with the Securities and Exchange Commission (the \u201c<span class=\"bwuline\">SEC<\/span>\u201d),<br \/>\n      and a solicitation\/recommendation statement on Schedule 14D-9 will be<br \/>\n      filed by Immune Design with the SEC. The offer to purchase shares of<br \/>\n      Immune Design common stock will only be made pursuant to the offer to<br \/>\n      purchase, the letter of transmittal and related documents filed as a<br \/>\n      part of the Schedule TO.\n    <\/p>\n<p>\n      <b>INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER<br \/>\n      OFFER STATEMENT AND THE SOLICITATION\/RECOMMENDATION STATEMENT REGARDING<br \/>\n      THE OFFER, AS THEY MAY BE AMENDED FROM TIME TO TIME, WHEN THEY BECOME<br \/>\n      AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.<\/b>\n    <\/p>\n<p>\n      Investors and security holders may obtain a free copy of these<br \/>\n      statements (when available) and other documents filed with the SEC at<br \/>\n      the website maintained by the SEC at <a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a><br \/>\n      or by directing such requests to the Information Agent for the Offer,<br \/>\n      which will be named in the tender offer statement. Additional copies of<br \/>\n      the tender offer materials may be obtained at no charge by contacting<br \/>\n      Merck at 2000 Galloping Hill Road, Kenilworth, N.J., 07033 or by phoning<br \/>\n      (908) 423-1000. In addition, Merck and Immune Design file annual,<br \/>\n      quarterly and current reports and other information with the SEC. You<br \/>\n      may read and copy any reports or other information filed by Merck or<br \/>\n      Immune Design at the SEC public reference room at 100 F Street, N.E.,<br \/>\n      Washington, D.C., 20549. For further information on the SEC public<br \/>\n      reference room, please call 1-800-SEC-0330. Merck\u2019s and Immune Design\u2019s<br \/>\n      filings with the SEC are also available to the public from commercial<br \/>\n      document-retrieval services and at the SEC\u2019s website at <a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>About Immune Design<\/b>\n    <\/p>\n<p>\n      Immune Design&nbsp;is a late-stage immunotherapy company employing<br \/>\n      next-generation&nbsp;<i>in vivo<\/i>&nbsp;approaches to enable the body&#8217;s<br \/>\n      immune system to fight disease. The company&#8217;s technologies are<br \/>\n      engineered to activate the immune system&#8217;s natural ability to generate<br \/>\n      and\/or expand antigen-specific cytotoxic immune cells to fight cancer<br \/>\n      and other chronic diseases.&nbsp;G100, the company\u2019s lead product candidate,<br \/>\n      is a potent intratumoral TLR4 agonist that has shown clinical benefit in<br \/>\n      multiple tumor types. Immune Design\u2019s technologies, the&nbsp;fundamental<br \/>\n      components of which were licensed from the&nbsp;California Institute of<br \/>\n      Technology&nbsp;and the&nbsp;Infectious Disease Research Institute&nbsp;(IDRI), also<br \/>\n      have potential application in infectious disease and allergy<br \/>\n      indications, which are being developed through ongoing pharmaceutical<br \/>\n      collaborations.&nbsp;Immune Design&nbsp;has offices in&nbsp;Seattle&nbsp;and&nbsp;South San<br \/>\n      Francisco. For more information, please visit&nbsp;<a href=\"http:\/\/www.immunedesign.com\" rel=\"nofollow\">www.immunedesign.com<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statements<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d that involve a<br \/>\n      number of risks and uncertainties. Statements that are not historical<br \/>\n      facts, including statements about our beliefs and expectations, are<br \/>\n      forward-looking statements. Such statements involve risks and<br \/>\n      uncertainties, which may cause actual results to differ materially from<br \/>\n      those set forth in these statements. For example, these forward-looking<br \/>\n      statements could be affected by factors including, without limitation,<br \/>\n      risks associated with the ability to consummate the proposed transaction<br \/>\n      described herein; general industry conditions and competition; general<br \/>\n      economic factors, including interest rate and currency exchange rate<br \/>\n      fluctuations; the impact of pharmaceutical industry regulation and<br \/>\n      health care legislation in the United States and internationally; global<br \/>\n      trends toward health care cost containment; technological advances, new<br \/>\n      products and patents attained by competitors; challenges inherent in new<br \/>\n      product development, including obtaining regulatory approval; our<br \/>\n      ability to accurately predict future market conditions; manufacturing<br \/>\n      difficulties or delays; financial instability of international economies<br \/>\n      and sovereign risk; dependence on the effectiveness of patents and other<br \/>\n      protections for innovative products; and the exposure to litigation,<br \/>\n      including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Additional factors that could cause results to differ materially from<br \/>\n      those described in the forward-looking statements can be found in each<br \/>\n      of Merck\u2019s and Immune Design\u2019s Annual Reports on Form 10-K and their<br \/>\n      other filings with the Securities and Exchange Commission (SEC)<br \/>\n      available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).<br \/>\n      Merck and Immune Design are under no obligation (and expressly disclaim<br \/>\n      any such obligation) to update or revise any forward-looking statement<br \/>\n      that may be made from time to time, whether as a result of new<br \/>\n      information, future developments or otherwise, except as required by law.\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck Media:<br \/>Pamela Eisele<br \/>(267) 305-3558<\/p>\n<p>       Merck Investors:<br \/>Peter Dannenbaum<br \/>(908) 740-1037<\/p>\n<p>       Courtney Ronaldo<br \/>(908) 740-6132<\/p>\n<p>       Immune Design Media:<br \/>Julie Rathbun<br \/>(206) 769-9219<\/p>\n<p>       Immune Design Investors:<br \/>Sylvia Wheeler<br \/>(650) 392-8318     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Immune Design (NASDAQ:IMDZ), today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Immune Design for $5.85 per share in cash for an approximate value of $300 million. \u201cScientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development,&#8221; said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThis acquisition builds upon Merck\u2019s industry-leading programs that harness the power of the immune system to prevent and treat disease.\u201d Immune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body&#8217;s immune system to fight disease. The company&#8217;s proprietary technologies, GLAAS \u00ae and ZVex \u00ae , are<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-746075","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Acquire Immune Design - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Acquire Immune Design - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Immune Design (NASDAQ:IMDZ), today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Immune Design for $5.85 per share in cash for an approximate value of $300 million. \u201cScientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development,&quot; said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThis acquisition builds upon Merck\u2019s industry-leading programs that harness the power of the immune system to prevent and treat disease.\u201d Immune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body&#039;s immune system to fight disease. The company&#039;s proprietary technologies, GLAAS \u00ae and ZVex \u00ae , are\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-immune-design\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-immune-design\\\/\",\"name\":\"Merck to Acquire Immune Design - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-immune-design\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-immune-design\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-02-21T06:45:00+00:00\",\"dateModified\":\"2025-05-12T12:58:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-immune-design\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-immune-design\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-immune-design\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-immune-design\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Acquire Immune Design\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Acquire Immune Design - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Acquire Immune Design - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Immune Design (NASDAQ:IMDZ), today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Immune Design for $5.85 per share in cash for an approximate value of $300 million. \u201cScientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development,\" said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. \u201cThis acquisition builds upon Merck\u2019s industry-leading programs that harness the power of the immune system to prevent and treat disease.\u201d Immune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's proprietary technologies, GLAAS \u00ae and ZVex \u00ae , are","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:19+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/","name":"Merck to Acquire Immune Design - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-02-21T06:45:00+00:00","dateModified":"2025-05-12T12:58:19+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-immune-design\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Acquire Immune Design"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"2379af4f-8d48-4d21-a016-d998b4584ad2","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2019\/02\/1\/244698_merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2019\/02\/1\/immune.jpg","size":"182491","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-to-Acquire-Immune-Design-2019.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746075\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746075"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}